Celleron targets Daiichi Sankyo with Roche's unwanted rare c...

UK biotech Celleron Therapeutics has bought a licence to develop, manufacture and market emactuzumab, an unwanted drug from Roche’s pipeline that could be used in a rare tendon sheath cance